JP2022519120A5 - - Google Patents
Info
- Publication number
- JP2022519120A5 JP2022519120A5 JP2021544864A JP2021544864A JP2022519120A5 JP 2022519120 A5 JP2022519120 A5 JP 2022519120A5 JP 2021544864 A JP2021544864 A JP 2021544864A JP 2021544864 A JP2021544864 A JP 2021544864A JP 2022519120 A5 JP2022519120 A5 JP 2022519120A5
- Authority
- JP
- Japan
- Prior art keywords
- nme7
- seq
- antibody
- peptide
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024171198A JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800941P | 2019-02-04 | 2019-02-04 | |
| US62/800,941 | 2019-02-04 | ||
| US201962830768P | 2019-04-08 | 2019-04-08 | |
| US62/830,768 | 2019-04-08 | ||
| US201962840769P | 2019-04-30 | 2019-04-30 | |
| US62/840,769 | 2019-04-30 | ||
| US202062965035P | 2020-01-23 | 2020-01-23 | |
| US62/965,035 | 2020-01-23 | ||
| PCT/US2020/016570 WO2020163325A1 (en) | 2019-02-04 | 2020-02-04 | Anti-nme antibody and method of treating cancer or cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024171198A Division JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519120A JP2022519120A (ja) | 2022-03-18 |
| JP2022519120A5 true JP2022519120A5 (cg-RX-API-DMAC7.html) | 2023-04-05 |
| JP7695193B2 JP7695193B2 (ja) | 2025-06-18 |
Family
ID=71947215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544864A Active JP7695193B2 (ja) | 2019-02-04 | 2020-02-04 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
| JP2024171198A Pending JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024171198A Pending JP2025020113A (ja) | 2019-02-04 | 2024-09-30 | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037413B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3920693A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7695193B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220016802A (cg-RX-API-DMAC7.html) |
| CN (2) | CN117264064A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020219046A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3128384A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285352A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020163325A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015243948B2 (en) | 2014-04-07 | 2020-10-15 | Minerva Biotechnologies Corporation | Anti-NME antibody |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| EP4161970A4 (en) * | 2020-06-08 | 2024-07-10 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES |
| CA3183682A1 (en) * | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2025049494A1 (en) | 2023-08-29 | 2025-03-06 | Minerva Biotechnologies Corporation | Bacterial nme7 orthologs and uses thereof |
| CN119931939B (zh) * | 2025-04-08 | 2025-08-15 | 上海交通大学医学院附属仁济医院 | 一种提升i型经典树突状细胞亚群诱导效率的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874285A (en) | 1996-09-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a novel human nm23-like protein |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| AU2003299643A1 (en) | 2002-12-04 | 2004-06-23 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| ES2624863T3 (es) * | 2005-06-08 | 2017-07-17 | Millennium Pharmaceuticals, Inc. | Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer |
| US20100254996A1 (en) | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| DK2334703T3 (en) | 2008-09-17 | 2015-10-05 | Innate Pharma | Configurations and methods for detection of tlr3 |
| EP3130607B1 (en) | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| WO2010042760A2 (en) * | 2008-10-08 | 2010-04-15 | The Administrators Of The Tulane Educational Fund | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens |
| MX2011013385A (es) | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN109456932A (zh) | 2011-10-17 | 2019-03-12 | 米纳瓦生物技术公司 | 用于干细胞增殖和诱导的培养基 |
| AU2013222935B2 (en) * | 2012-02-24 | 2016-03-10 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014018679A2 (en) | 2012-07-24 | 2014-01-30 | Minerva Biotechnologies Corporation | Nme variant species expression and suppression |
| WO2014028668A2 (en) | 2012-08-14 | 2014-02-20 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| CA2886161A1 (en) | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| US20160326263A1 (en) | 2013-02-20 | 2016-11-10 | Minerva Biotechnologies Corporation | NME Inhibitors and Methods of Using NME Inhibitors |
| CA2901893C (en) | 2013-02-20 | 2022-08-30 | Minerva Biotechnologies Corporation | Nme inhibitors and methods of using nme inhibitors |
| AU2015243948B2 (en) | 2014-04-07 | 2020-10-15 | Minerva Biotechnologies Corporation | Anti-NME antibody |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| CN108409862B (zh) | 2016-07-14 | 2021-07-13 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
| WO2018054240A1 (en) | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pcsk9 antibodies |
| CA3039797A1 (en) * | 2016-10-11 | 2018-04-19 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and use of cleavage enzyme |
| WO2019104306A1 (en) | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| EP4161970A4 (en) | 2020-06-08 | 2024-07-10 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
-
2020
- 2020-02-04 EP EP20752059.4A patent/EP3920693A4/en active Pending
- 2020-02-04 CA CA3128384A patent/CA3128384A1/en active Pending
- 2020-02-04 AU AU2020219046A patent/AU2020219046A1/en active Pending
- 2020-02-04 CN CN202311184872.3A patent/CN117264064A/zh active Pending
- 2020-02-04 CN CN202080024809.1A patent/CN113727602B/zh active Active
- 2020-02-04 KR KR1020217028113A patent/KR20220016802A/ko active Pending
- 2020-02-04 JP JP2021544864A patent/JP7695193B2/ja active Active
- 2020-02-04 WO PCT/US2020/016570 patent/WO2020163325A1/en not_active Ceased
-
2021
- 2021-08-03 IL IL285352A patent/IL285352A/en unknown
- 2021-08-03 US US17/392,981 patent/US12037413B2/en active Active
-
2024
- 2024-06-03 US US18/731,929 patent/US20240392038A1/en active Pending
- 2024-09-30 JP JP2024171198A patent/JP2025020113A/ja active Pending